TY - JOUR
T1 - A preliminary report of the effects of orally administered enoximone on regional hemodynamics in congestive heart failure
AU - Leier, Carl V.
AU - Meiler, Steffen E.L.
AU - Matthews, Sally
AU - Unverferth, Donald V.
N1 - Funding Information:
From the Division of Cardiology, College of Medicine, The Ohio State University Hospitals, Columbus, Ohio. This study was supported by a grant from Merrell Dow Pharmaceuticals, Inc., Cincinnati, Ohio.
PY - 1987/8/14
Y1 - 1987/8/14
N2 - Twelve patients with moderately severe congestive heart failure underwent the simultaneous determination of central and regional hemodynamics after administration of placebo and enoximone. The regions examined hemodynamically included renal, hepatics-planchnic and upper limb. Enoximone was studied in 2 doses, 1 and 2 mg/kg, and administered in a double-blind, placebo-controlled, crossover design. At these doses enoximone elicited a significantly greater increase in cardiac output and a greater decrease in systemic vascular resistance than placebo. Systemic blood pressure was not significantly altered. Enoximone did not significantly change the flow or resistance of renal or hepatic-splanchnic vascular beds. Limb vascular resistance decreased modestly after enoximone with a significant augmentation (+12% to 17%) of limb blood flow compared with placebo. The initial oral administration of the 1 and 2 mg/kg doses of enoximone improved central hemodynamic parameters with apparent preferential reduction of limb vascular resistance and augmentation of blood flow to the limb region (peripheral musculoskeletal system).
AB - Twelve patients with moderately severe congestive heart failure underwent the simultaneous determination of central and regional hemodynamics after administration of placebo and enoximone. The regions examined hemodynamically included renal, hepatics-planchnic and upper limb. Enoximone was studied in 2 doses, 1 and 2 mg/kg, and administered in a double-blind, placebo-controlled, crossover design. At these doses enoximone elicited a significantly greater increase in cardiac output and a greater decrease in systemic vascular resistance than placebo. Systemic blood pressure was not significantly altered. Enoximone did not significantly change the flow or resistance of renal or hepatic-splanchnic vascular beds. Limb vascular resistance decreased modestly after enoximone with a significant augmentation (+12% to 17%) of limb blood flow compared with placebo. The initial oral administration of the 1 and 2 mg/kg doses of enoximone improved central hemodynamic parameters with apparent preferential reduction of limb vascular resistance and augmentation of blood flow to the limb region (peripheral musculoskeletal system).
UR - http://www.scopus.com/inward/record.url?scp=0023261959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023261959&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(87)90521-2
DO - 10.1016/0002-9149(87)90521-2
M3 - Article
C2 - 2956864
AN - SCOPUS:0023261959
SN - 0002-9149
VL - 60
SP - 27
EP - 30
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
IS - 5
ER -